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The role of Mycobacterium avium subsp paratuberculosis (MAP) in the etiology and
pathogenesis of inflammatory bowel disease (IBD) including Crohn's Disease (CD), has been
investigated.  The fastidious characteristics and cross reactivity of MAP with other members in
Mycobacteria have produced significant challenges in their detection and identification.  In this
two year pilot study, an array of three PCR molecular assays based on  the detection of sequences
from the16S rRNA, IS1245, and IS900 genes, belonging to members of the MAC, have been
developed and optimized into a common protocol to be used as a rapid and accurate diagnostic
tool regarding M. avium complex (MAC) infection.  The PCR protocol time was reduced by half,
and the sensitivity and specificity of the molecular assays has been significantly improved
barring the need for southern hybridization. This improved methodology was employed for the
molecular typing of MAC in 100 resected, full-thickness tissue samples removed frm IBD
patients.  The tissue samples were homogenized, decontaminated, and inoculated into two
mycobacterial culture media systems.  A total of 328 Bactec and Mycobacteria Growth Indicator
Tube (MIGT) cultures were evaluated for positive MAC growth.  Harvested cells were th n
subjected to genomic DNA extraction and subsequent PCR typing.  The I6 S rRNA-based PCR
resulted in detection of 26/28 (93%) MAC in Bactec cultures.  Specifically, 25/28 (89%) of
positive MAC indicated the presence of IS1245 specific to M. avium subsp avium (MAV), and
6/28 (21%) produced results consistent with the presence of IS900 following nested PCR.
Moreover, 20/100 (20%) of MGIT cultures were positive for MAP.  Sequence analysis was
performed on amplified regions of the IS900 element from seven isolates.  A nucleotide
alignment revealed that 2/7  isolates demonstrated 100% homology to Bovine MAP and 5/7
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isolates showed 96-99% homology to sequenced Bovine MAP published in GenBank. The
detection of at least two Bovine derived MAP in IBD tissue will have great impact on the
epidemiology and reclassification of IBD. The significant homology of the other five isolate  to
Bovine derived MAP suggests a diversity in the geographical distribution of MAP regardin
Johne's disease and CD.  Ultimately, the etiology, diagnosis, and the treatment of IBD as well as
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 INTRODUCTION
 History of   Crohn’s   Disease 
In 1932, B.B. Crohn, along with colleagues Ginzberg and Oppenheimer, published a landmark
paper entitled “Regional Ileitis” that would forever coin a disease while sparking deep
controversy in the scientific community that still lingers today (14, 10).  Although the term
Crohn's disease (CD) is a relatively new term, the disease itself is thought t have first been
described in 1682 (36, 10).   It was Dalziel, however, in 1913, that laid the groundwork for the
recognition of CD as distinct from other intestinal disorders, when he observed striking
similarities between what he termed “intestinal enteritis” and pseudotuberculosis found in cattle
(17), today called paratuberculosis or Johne's disease (JD)  (10, 73).  Often confused with
intestinal tuberculosis, this chronic enteritis so mirrored Johne's both pathologically and
histologically that logical suspicions arose that they may share the same acid-fast bacilli as their
etiological agent (13, 10).  Although Dalziel was unsuccessful in isolating mycobacteria from the
intestinal enteritis patients, he still held fast to an infectious etiological theory stating (17, 10):
“In many cases the absence of acid-fast bacilli would suggest a clear distinction, but the
histological characters are so similar as to justify a proposition that the diseases may be the
same.”  But, without clear evidence for a bacterial origin, the mycobacterial theory for this
baffling disease faded in the scientific community (52, 10).  Thus, the intestinal disorder was
reclassified as a tubercle disease until Crohn distinguished it once again as a sep rate ailment.
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However, because he was unable to fulfill Koch's postulates, he proposed CD as an autoimmune
disorder (14, 10).  And thus, to this day, the scientific community continues to grapple with the
origins of this disease, with new technologies sparking renewed interest into the old theory that
CD will some day be demonstrated to have a mycobacterial etiology.
 Clinical Aspect of Crohn's Disease  
Crohn's is a type of inflammatory bowel disease usually manifesting itself in the terminal ileum.
However, any part of the gastrointestinal (GI) tract can be involved including the mouth, larynx
esophagus, stomach, and colon.  Crohn's cases have also been demonstrated in the muscle,
synovial tissue, bone, and skin (10).  This chronic enteritis differs from other colitis diseases in
that it causes transmural inflammation of the gut characterized by non-caseating gr nulomas,
micro-fistula formation, and ulcerative fissures (57, 50).  These deep clefts cause the intestinal
mucosa to become patchy and segmented and give the appearance of cobblestone, a classic
symptom of Crohn's (22).  Other common features include pain and tenderness in the lower right
quadrant mimicking acute appendicitis.  Intestinal stenosis also occurs causing obstructi n of the
lumen, abdominal distention, constipation, and occasionally vomiting.  Intestinal bleeding due to
granulomatous and ulcerative lesions can induce diarrhea eventually leading to malabsorption
and weight loss (22, 57).  Crohn's is a life-long disorder leaving patients to endure unpredictable
periods of relapse and remission.  Because there is no cure, their quality of life can be severely
compromised as a result of these recurring episodes (22). 
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 Crohn’s Disease Epidemiology: Incidence and Prevalence  
Because most epidemiological studies to date have concentrated on specific regions or
populations within a country, the full extent to which CD has reached cannot be completely
grasped. However, these studies have defined certain attributes of the disease that provide clues
to Crohn's etiology.  For instance, Crohn's is a slow progressing condition primarily strik ng in a
person's prime of life, most commonly between the ages of 15-40 years of age (22).  Men and
women are affected equally with the majority of cases reported in Northern Europe and North
America (22, 15, 67).  Some reports have demonstrated a possible heritable link among Crohn's
patients, with 20-25% having a close relative with IBD, while others have pointed strictly to
environmental agents as culprits of disease (74, 37).  Although the ethnic and geographical
distribution of the disease in the U.S. had not been extensively studied in decades past, Dr.
Loftus, in 1997, did provide a glimpse into the prevalence of IBD in a report using information
gathered by the Rochester Epidemiology Project (44).  According to this unique records linkage
system, 133 persons in 100,000 living in Olmsted County, Minnesota, suffer from Crohn's with
5.8 new cases in the same population every year.  The results of this publication were based upon
the Caucasian community with comparable numbers likely in African-American and Hispanic
populations.  Furthermore, people of Jewish heritage were found to be 4 to 5 times more likely to
contract IBD than people in the general population.  When these statistics were applied to the rest
of the country, Dr. Loftus extrapolated that approximately 500,000 people have Crohn's in the
U.S.  (15,  44).  Conversely, a group of pediatricians have shown through their two year study
that children in Wisconsin contracted IBD with an incidence of 7.05 per 100,000.  The
distribution of disease was equal among all ethnic groups and geographical locales.  The rate of
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CD was nearly double that of Ulcerative colitis (UC) cases with 89% being non-familial
incidences (37).   Taken together, data collected from these recent studies supports the roposal
that CD is a multi-factorial disease whose complete etiological spectrum is still emerging, with
some cases involving an inherited component of susceptibility to environmental pathogens whil
others seem to be explained by unfavorable external conditions and exposure.  According to Dr.
Loftus, studies such as these that are concentrated to a particular area or region se ve to limit a
global understanding and picture of Crohn's epidemiology.  Several factors may contribute to
such diverse results in these epidemiological studies such as different methodologies employed
as well as diverse genetic and environmental agents present in the different populations.
Consequently, Dr. Loftus has proposed a national longitudinal database of Crohn's patients as a
tool to better define the incidence, prevalence, and geographical distributions of disease (43).
 Crohn’s Disease Diagnosis and   Methodology  
CD can be difficult to distinguish as it is easily confused with other intestinal disorders.
Consequently, an extensive physical exam and panel of blood tests may be required for accurate
diagnosis.  A low red blood cell count could indicate anemia, an evidence of bleeding in the
intestines.  Further, a high white blood cell count would signify a sure sign of inflammation in
the body.  A stool sample may also be helpful in determining intestinal hemorrhaging or
infection.  An upper GI will allow the small intestine to be checked for any obvious
abnormalities.  Before X-rays are taken, patients drink a white, chalky solution composed mainly
of barium that coats the small intestinal lining.  The white contrast of the barium reveals
inflammation or lesions that may be present.  To view the large intestine, the doctor may use an
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endoscope, a light mounted at the end of a long flexible tube, to perform a colonoscopy at which
time a biopsy may be taken for further analysis.  The sampled tissue may be viewed under the
microscope to confirm the level of inflammatory tissue involvement (57, 15).  Ideally,
immunological tests based upon sera cross-reactivity or DNA detection via PCR could clearly
diagnose CD if associated with an infectious agent.  
 Crohn’s Disease and Mycobacteria  
The genus Mycobacterium contains over seventy validly named species with thirty-two known
animal and human pathogens.  All mycobacteria are aerobic, gram-positive, straight or curved,
mesophilic bacilli.  The non-motile rods are easily distinguished from other bacteria by their
resistance to alcohol-mediated decolorization termed acid-fast positive (60).  This classic
mycobacterial feature is due to their thick, waxy cell wall composed primarily of mycolic acids
and arabinose derivatives (24).  Their genomes are GC-rich, about 59-66% of their total DNA
content, and share very similar homology with few antigenic determinants (45, 1, 5).
Mycobacteria can be assigned to two broad categories based on their reproductive growth rates.
Most pathogens, like Mycobacterium tuberculosis complex and Mycobacterium avium complex
(MAC), belong to the slow-growers requiring at least seven days to produce visible colonies n
solid media under controlled conditions (45, 70).  They survive mainly from host to host while a
few species, including some MAC, survive in environmental reservoirs as the fast-growers.  The
MAC includes several subspecies including M. avium subspecies avium (MAV) M.
intracellulare (MI), M. avium subspecies ilvaticum (MAS), and M. avium subsp.
paratuberculosis (MAP).  Both MAV and MAP grow best on egg yolk and OADC supplemented
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Middlebrook media at 37 oC.  However, they differ in that MAV will produce yellow colonies
after seven days of incubation, whereas it can take 3-6 weeks to grow the whitish colonies of
MAP.  Another difference is that MAP is mycobactin-dependent, while MAV produces its own
iron-chelating siderophore (20, 77).  There are few genotypically distinct characteristics to
separate the two subspecies.  Recent genomic mapping and bioinformatics studies recognize
three such differences among the MAC subspecies.  MAP contains 14 to 18 copies of the IS900
insertion sequence, identifiable by PCR and Southern hybridization, a 6,496 bp single cassette
responsible for biosynthesis of surface carbohydrate, and an additional 11kb section of DNA
located in the IS900 element (68, 29, 5).  Moreover, MAP is the confirmed inflammatory agent
of JD in cattle and other ruminants, whereas MAV is considered an opportunistic pathogen,
usually found in immuno-compromised patients (26, 28).
 Crohn’s Disease Etiology: Theories and Reality  
Much debate concerning the etiology of CD has been argued in the scientific literature since
Crohn re-distinguished it as a separate disorder in 1932.  Everything from diet and environmental
pathogens to autoimmunity and genetic aberrations have been implicated as playing possible
roles in the pathology of Crohn's.  Innovative research via new technologies is beginning to shed
light on the true origins of Crohn's which may actually involve several etiological factors.  This
current research hypothesizes that acquiring CD is the result of a genetic predisposition that is
exploited by an environmental trigger, namely a bacterial pathogen, causing an abnormal
immune response (35, 8, 65, 23).  
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 The Genetic Susceptibility Factor
In order to more clearly understand whether CD is an inherited or acquired disorder, many
investigators have explored the familial occurrence of the disease.  Scientists have discovered a
greater than expected incidence for site and clinical type of CD within individual families.  A
pattern of young age onset and disease complications was also uncovered in correlated familial
cases as compared to isolated incidences.  These studies provide strong evidence that gen tic
factors are significant determinants of CD susceptibility and pathology (2).  Statistical rates of
disease in siblings and monozygotic twins further implicate a genetic contribution to acquisition
of disease that is equivalent to other immune-mediated disorders such as multiple sclerosis and
insulin-dependent diabetes (22, 62, 63).  Several genetic loci have been analyzed as possible
factors in the development of CD.  One such recently discovered gene called NOD2/CARD15
may prove to be a catalyst for ground-breaking genetic and therapeutic advances.  Located in the
IBD1 locus on chromosome 16q12, it is thought to encode a disease resistance protein on
monocytes, similar to anti-microbial proteins expressed in plants (58, 34, 59).  NOD2/CARD15
belongs to a family of intracellular protein receptors called NBS-LRR (nucleotide-binding site;
leucine-rich repeat) that have been demonstrated to recognize the peptidoglycan motif of
bacterial pathogens by binding the MDP (muramyl dipeptide) component.  Once activated by th
bacterial cell wall, NOD2/CARD15 is capable of inducing NfkappaB, a key pro-inflammatory
pathway responsible for the production of several immuno-regulators such as cytokines and
chemokines (7, 78, 59).    Further experimental data find that NOD2/CARD15 is upregulated by
specific cytokines, namely TNF-alpha, thereby amplifying the immune response and facilitating a
continuous cycle of inflammation (31, 61); the overexpression of NOD2/CARD15 seen in CD
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patients serves to further explain this exaggerated immune response associated with Crohn's (3).
A frameshift mutation in NOD2/CARD15, caused by a cytosine insertion, as well as sveral
single-nucleotide polymorphisms have been shown to decrease the innate immune system's
ability to recognize certain pathogens, particularly in cases of ileal CD versus colonic disease
(16).  This selective association is supported by the finding that the NOD2/CARD15 gene is
found most abundantly in paneth cells, which are located primarily in the terminal ileum where
they serve as a major host defense against gut microbes (40).   Inherited defects in
NOD2/CARD15 have been observed in 30-50% of CD patients compared to 7-20% of healthy
controls (31).  The fact that NOD2/CARD15 gene mutations have been positively correlated to
the contraction of Crohn's provides one of the first physical links between an infectious agent and
irregular immune response at the molecular level (58, 31). 
 Why is Mycobacterium a Good Candidate for Crohn's Disease Pathogenesis?
The remarkable similarities between CD and other well-documented mycobacterioses in humans
and animals have kept researchers returning to the theory that CD has its etiology rooted in
mycobacterial infection (74, 20, 42, 9, 29, 32, 13, 54, 26).  The parallels between CD and JD
remains one of the best arguments for this hypothesis.  The pathology and symptoms of Johne's
or bovine paratuberculosis infection was first described as early as 1806 by Professor Edward
Skellet in his book entitled Parturition of the Cow (38).  However, it was Johne and Frothingham
who are said to have first documented these symptoms as a disease by demonstrating a link
between mycobacteria and paratuberculosis in ruminants (73).  
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Upon receiving the tissues of a cow, from a local German farmer, thought to have succumb to
intestinal tuberculosis, Johne and Frothingham performed a histological examination where they
found an abundance of immune cells in the abnormally thick, intestinal mucosa and wall
including leukocytes and epitheliod cells.  Acid-fast staining and microscopic evaluation of he
ruminant intestine revealed colonies of acid-fast micro-organisms similar to Mycobacterium
bovis, the bacteria that causes tuberculosis in cattle.  Because the sample failed to cause disease
in guinea pigs, Johne classified the discovery as Mycobacterium avium, the pathogen responsible
for tuberculosis in birds (73).  Today, scientists have further typed that organism more
specifically to MAP.  
The connection between these histologically inseparable disorders is strengthened by vidence
that Johne's may be easily transmitted to cattle and other mammalian populations including
humans (29).  Originally considered a disease strictly affecting dairy cows, Jhne's is most
prevalent in cattle with approximately 40% of all U.S. dairy herds containing at least one infected
animal.  Calves are often infected through their mother's colostrum and milk (69).  However,
Johne's may be spread via the fecal/oral route to other species including sheep, pigs, goats, and
horses.  Once mycobacterial exposure and colonization occur, infection originates in the Peyer's
patches where gut pathogens are absorbed through M cells to be phagocytized by macrophages.
Due to their thick, waxy cell wall, the mycobacteria are able to evade degradation in the
phagolysozome normally caused by low pH molecules like nitric oxide.  Consequently, the
pathogens thrive undetected perpetuating the infection and risk of transmittance (51, 72).
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Furthermore, there is compelling data to suggest that the parasitic mycobacteria that cause
Johne's can be disseminated throughout the human food chain.  Several studies testing thermal
tolerance of mycobacterial species concluded that several M. avium subspecies including
paratuberculosis are capable of penetrating the dairy supply by surviving the pasteurization
process (29, 45, 8, 25, 48).  The pathogenic organisms persist by migrating to the cow's udder
within protective leukocytes where they directly contaminate excreted milk.  Ground beef as well
as dairy can be considered a potential source of human exposure to infectious mycobacteria,
especially since most animals are slaughtered or milked before the manifestation of disease.
Ground water contamination is yet another means of possible animal to animal or animal to
human transmittance (8, 22).  Surface waters which feed into domestic water supplies often
contain agricultural waste runoff.  Studies have revealed that M. vium is not eliminated by
common water treatment practices which include filtration and chlorination (22, 8, 29).  
Pathological comparison of CD to other mycobacterial diseases, namely tuberculosis and leprosy,
provide additional credibility to the notion that CD etiology is directly linked to the
mycobacterial family.  The progression of CD symptoms manifest extremely si i ar to that of
tuberculosis.  Often Crohn's and intestinal tuberculosis have indistinguishable pathologies, nly
characterized by specific molecular typing via polymerase chain reaction and acid-fast staining.
Mycobacterial disease usually presents in two major forms:  contained or aggressive.  A
contained or tuberculoid/non-perforating response to infection is described mainly by the
presence of granulomas that eventually lead to chronic intestinal obstruction (35, 49).  The
aggressive or perforating form is characterized by severe ulcerations in the intestinal wall that
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advances to fistulas, abnormal connections or pathways between sections of bowel.  Both of
these forms have been documented in Crohn's patients and sometimes display a “dual
presentation.”  The spectrum of acquired symptoms is thought to be based upon a patient's cell-
mediated immune response to pathogenic mycobacterial antigens, suspected to be an inherited
trait (35).  
Success in treating Crohn's with a cocktail of anti-mycobacterial drugs gives even furth r
evidence that CD can be ascribed to mycobacterial infection.  Macrolide antibiotics are essential
in treating most mycobacterial diseases due to their ability to penetrate macroph ges and
metabolizing immune cells thereby eradicating the intracellular pathogens (9, 46).  These
medications which include clarithromycin and azithromycin need to be administered in
combination with other macrolide drugs like rifabutin, a common anti-tuberculosis treatment, in
order to combat the phenomenon of multi-drug resistance.  For instance, in 1997 Hermon-
Taylor's study of 52 diagnosed Crohn's patients demonstrated a 93.5% clinical remission rate
after treatment with rifabutin in combination with clarithromycin or azithromycin for six months.
Many patients maintained remission status with no symptoms for up to two years depending
upon the severity of prior disease (27).
 The Host Immune Response
Some proponents still debate mycobacteria as the true etiology of CD based upon the ambiguity
surrounding the current evidence of a specific immune response to MAP in CD patients.  It is
clear that most Crohn's sufferers demonstrate a much different and unexpected immune reaction
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as compared to victims of many other infectious agents (18, 35).   The anergic immune reactions
demonstrated in CD patients are driven by an elevated Th1 cytokine profile, including IL-12 and
INF-gamma, (4) that induces a damaging type of chronic inflammation as opposed to Th2
cytokines that promote a healing immune response (9, 39).  However, several pathogenic micro-
organisms have been identified, including Mycobacterium tuberculosis and Mycobacterium
leprae,  that have evolved sophisticated measures to circumvent the human immune system
producing similar dysregulated immune responses (35).  For instance, as intracellular parasites,
the microbes that comprise the Mycobacterium family target and inhabit macrophages, the
primary immune cells responsible for destroying invading bacteria.  By resisting degradation in
the phagolysozome, the bacteria are able to avoid normal antigen presentation, thereby creating a
type of pathogenic “sanctuary” where they can thrive protected from the threat of other immune
cells (30).  Other mycobacteria species, like M. leprae, actually impede the actions of the cell-
mediated immune response by suppressing the production of cytokines in the host (71).  Still,
some bacterial species possess antigenic epitopes strikingly similar to that of host molecules.
These shared components can elicit a perpetual molecular mimicry state, analogous to the
mechanisms of autoimmunity, whereby bacterial antigens appear as self antigens, thus e caping
detection by the immune system. This phenomenon has been investigated concerning
mycobacterial heat shock proteins and outer envelope polysaccharides due to their homology to
human epitopes.  However, concrete evidence of molecular mimicry in these cases has yet to be
established (35, 19, 41).  Moreover, antigen-antibody investigations into the Crohn's immune
response may be hampered by sero-cross reactivity caused by the many shared antigens among
species of mycobacteria.  Some pathogenic mycobacteria have up to a 65% cross-reactivity ate
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as a result of such close homology between their antigens (18, 35).  Consequently, statistical
results concerning control groups versus test subjects can be skewed by patients unknowingly
exposed to different mycobacterial organisms (9, 75). Therefore, it is imperative to discover
immunogenic antigens that are specific to MAP in order to more thoroughly study the potential
of a mycobacterial etiology associated with CD.   It is bacterial survival strategies such as these
coupled with other determinants such as the genetic make-up of the host and organism and
environmental factors that serve to cloud a definitive understanding of the immuno-modulatory
responses that are initiated by mycobacterial infection.  
 Spheroplast Versus Bacillary
CD has long been suspected of having an etiological relationship to mycobacteria, ever since its
recognition as a distinguishable condition in the early twentieth century.  However, attempts by
researchers to establish a link between CD and mycobacteria proved frustrating after continual
failures to isolate and culture acid-fast bacilli from infected Crohn's tissue. But, when Chiodini
et. al. were the first to isolate an unclassified mycobacterial species from th ee Crohn's patients in
1984, enthusiasm was again sparked in the scientific community concerning a plausible
connection between CD and mycobacteria (9, 10, 11).  With this success came new insights into
the prior inability of investigators to detect mycobacteria in Crohn's tissue.  Chiodini s on found
that these primary isolates lacked a definitive cell wall only reverting to bacillary form after
months of incubation on supplemented media.  Restriction polymorphism techniques revealed
the genetic identity of these bacteria as MAP (9, 10, 12).  It is now understood that MAP survives
in two states:  spheroplast and bacillary forms.  Current theories postulate that MAP becomes an
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invasive human pathogen in its spheroplast form as opposed to the bacillary form that infects
ruminants (9, 33).  Spheroplasts are characterized by a partial loss of cell wall with resistance to
acid-fast staining, increased sensitivity to osmotic pressures, and dependence on iron-scavenging
compounds such as mycobactin.  Several genes specific to MAP are now thought to regulate the
expression, modification and transfer of the sugar fucose to cell wall GPL's (glycopeptidolipids).
These oligosaccharide moieties coating the cell may contribute to the bacteria's ability to adopt
an acid-fast and protease resistant, non-bacillary form (68, 66).  Attributes such as these
combined with harsh processing techniques used in mycobacteriology, which can damage the
exposed cell membrane,  further complicate culture and subsequent identification of MAP in
Crohn's tissue.  Even if proper growing conditions are met, identification of MAP depends upon
the spheroplast achieving an intact cell wall with recognizable morphology, which can take
several months to a year decreasing the probability of recovering viable organisms (9, 47, 35).
The presence of spheroplasts may explain the limited immune response observed in most CD
patients.  Cell wall deficient bacteria often have poor immunogenic properties due to diminished
envelope epitopes but retain the ability to evoke a local hypersensitivity reaction seen in chronic
CD (35).
 Variability in Laboratory Techniques
The multi-faceted complications associated with the detection of MAP in CD tissue can serve to
undermine the  logical correlation of mycobacteria to this intestinal disorder if not properly
assessed.  MAP had eluded the most erudite scientists for decades until Chiodini discovered
ground-breaking information in the 1980's concerning its nature and requirements for tissue
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culture (10).  Similarly, researchers are beginning to recognize and correct the reasons behind
years of inconsistent experimental results concerning MAP detection in CD.  The understa ing
that MAP may be present in different distributions and forms throughout diseased tissue may b
the key to unlocking the variability observed in the efficiencies of several laboratory detection
techniques.  For instance, in animals, JD is seen in a pluribacillary or paucibacillary form with
little to no MAP detected in the latter (35).  This may extend to humans whereby spheroplasts are
often sparsely scattered throughout CD tissue making them difficult to recover.  The efficiency of
DNA extraction is imperative in the detection of MAP in CD tissues.  The lack of adequate
spheroplasts coupled with different extraction methods have proven to dramatically affect MAP
detection.  The preparation of experimental tissue has also been recently called into question.
Traditional paraffin-mounted tissue has shown to contain inhibitors that interfere with PCR
amplification of MAP (77).  Furthermore, different PCR reagents and protocols range in their
sensitivities for the amplification of certain mycobacteria fragments (27).  The development of
laboratory techniques that address these complications to better identify mycobacterial species in
diseased tissue is, therefore, essential in establishing the foundation of Crohn's eti logy.
 Rationale and Objectives   
Data supporting the role of MAP in CD etiology is mounting, yet there is still considerable
skepticism regarding the role that MAP or MAP-like organisms may play in this disease.
Therefore, consistent protocols that accurately conclude the presence or absence of MAP in
specimens from CD patients are urgently needed.   The recent introduction of Bactec and MGIT
enriched liquid culture systems and IS900 specific PCR assays have greatly improved MAP
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detection.  However, the transposable IS900 element has been found in other Mycobacterium
species in co-infected patients, such as those with IBD and HIV, which suggests that still more
approaches are required to enhance the specificity and sensitivity of MAP detection in Crohn's
tissue.  The close homology of MAC subspecies and the possibility of IS900 lateral transfer to
other MAP-like derivatives underscores the importance for the accurate identification and study
of epidemiological versus geographical distributions of MAP (53).  In an attempt to investigat
the role of mycobacteria in IBD, especially CD,  the objectives of this study were as follows:  1)
to culture MAC and/or MAP from Crohn's biopsied tissue,  2)  to design a sensitive, efficient
PCR protocol for the detection of MAC in CD tissue, 3)  to identify a library of mycobacteri l
isolates through molecular typing techniques, 4)  to evaluate a set of representative DNA
sequences in order to investigate homological and epidemiological differences among isolates.  It
is hoped that the outcome of this study will guide future endeavors toward better approaches
when investigating the mycobacterial role in Crohn’s disease etiology and epidemiology.
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  MATERIALS AND METHODS
 Specimen Processing  
 Specimen Collection and Logging
The full thickness surgical tissues used in this study were kindly collected and shipped to th
University of Central Florida by collaborators at Mt. Sinai hospital in New York.  The tissue
samples were cataloged blindly and referred to only by their assigned code (ex. MS1, MS2, MS3,
etc.).  All reference information including dates of arrival and processing were recorded.  The
specimens were packaged on ice and received cold but not frozen.  Normal tissue and inflamed
tissue specimens from each subject were collected if possible.  Figure 1 shows the form that was
used to document each incoming sample.
 Homogenization and Decontamination
All tissue samples were processed within a class II Biosafety facility. Proper laboratory attire,
such as latex gloves and a laboratory coat, were worn at all times to ensure the safety of the
laboratory environment and the integrity of each specimen.  Samples arriving to the laboratory
were immediately unpacked, removed from ice, and transferred from their sterile glass vial
containers to a fresh 50 mL centrifuge tube.  The tissue was then placed into a disposable 50 mL
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tissue grinder until completely homogenized.  The ground tissue was decontaminated to eradicate
all extracellular organisms by the addition of 5 mL of BBL MycoPrep NALC-NaOH (n-acetyl-L-
cysteine-NaOH) solution.  The centrifuge tube containing the MycoPrep/tissue mixture was
vortexed for 1 minute and allowed to set at room temperature for 20 minutes, with intermittent
swirling.  The final volume of the mixture was brought up to 50 mL with phosphate buffer
solution (PBS, NA2HPO4, KH2PO4, pH 6.8) followed by centrifugation at 3,000 rpm for 20
minutes at room temperature.  The supernatant was discarded, and the pellet was washed twice in
1 mL of PBS at 10,000 rpm at 4o C before being suspended in a final 1 mL volume of PBS (64,
55).
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Figure 1.  Documentation and Tracking Form for each Tissue Received.
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 Culture and Growth Condition
A 0.5 mL portion of each homogenized, decontaminated tissue specimen was aseptically
inoculated into two types of supplementally enriched, liquid media specific for the growth and
support of mycobacteria as follows:  
 The Bactec Culture System  
Bactec 12B Mycobacteria liquid culture Media works as part of a system of mycobacterial
growth detection in conjunction with the Bactec 460TB Reader.  The basic medium consists of
Middlebrook 7H9 broth as a base with the addition of catalase, casein hydrolysate, bovine serum
albumin, and 14C labeled palmitic acid.  The media was enriched with several types of
supplements to further support the cell wall growth of MAC, in particular the elusive membrane
of subspecies paratuberculosis.  These include 0.5 mL of BBL OADC, which contains oleic
acid, bovine albumin, dextrose, and catalase; 0.1 mL BBL Panta broadspectrum antibiotic
cocktail which includes polymixin B, amphotericin B, nalidixic acid, trimethoprim, and
azlocillin; and 0.016 mL Mycobactin J (2 mg/L), an iron chelator molecule. Furthermore, a
duplicate Bactec culture was prepared for each sample that contained all previously mentioned
ingredients with the addition of 1 mL Bacto 50% Egg Yolk Enrichment (Difco) to further
enhance mycobacterial cell wall synthesis. All aseptically inoculated Bactec culture bottles were
then incubated in a 5% CO2  incubator at a constant 37o C.  Approximately every three to five
days from the date of inoculation, the Bactec culture bottles were placed into the automatic
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Bactec 460 TB analyzer to measure the amount of 14C labeled CO2 emitted by the mycobacterial
organisms during growth. (64, 55) 
 Bactec 460 TB Growth Detector  
Inoculated mycobacteria that grow within the Bactec 12B vial utilize provided nutrients,
especially 14C labeled palmitic acid, in order to synthesize new cell wall as they divide.  The
expanding population of organisms emits 14CO2 as a by-product of respiration that is proportional
to the level of cell division and is measured by the Bactec analyzer as growth index.
Determination of a sample's growth index begins once the vials are loaded sequentially into the
Bactec reader.  First, however, a standard Bactec bottle containing a pre-determined volume of
14CO2 is initially used to calibrate the instrument.  The CO2  gas by-product is drawn from the
Bactec bottle by a sterile needle attached to a robotic arm.  Once aspirated into the needle, the
CO2 is pushed through the system into a CO2 trap as a result of surrounding air being drawn into
the needle through a dust filter and into the ion chamber via a flush valve.  The electrometer is
thus cleaned and ready for the next sample in the cycle.  When two 18G needles are heated, the
robotic testing needle is driven through the rubber septum of the test vial provided by the
manufacturer (Becton-Dickinson).  Extracted 14CO2 from the sample is drawn into the ion
chamber by a pump-driven vacuum.  The radioactively labeled CO2 present in the given sample
creates a tiny electric current which is detected by the electrometer in th  ion chamber.  This
current is then magnified and displayed as the sample's growth index (GI).  The labeled CO2 used
to measure cell growth in an individual vial is replaced by a volume of fresh 5% CO2 to continue
the promotion of mycobacterial growth in the Bactec bottle.  The growth index is measured
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according to a scale of 0, meaning no detected growth, to 999, indicating maximum level of
microbial activity.  Samples registering a GI of 10 or greater, a threshold a positive growth, are
usually returned to the incubator to allow more time for advancement.  Vial contents that give 
reading of 999 are harvested, with a portion inoculated into fresh Bactec media. Figure 2 shows
illustration of the Bactec 460 TB analyzer.
 The MGIT (Mycobacterial Growth Indicator Tube) culture system
The MGIT system uses an oxygen-sensitive growth indicator that  fluoresces as oxygen levels
decrease due to bacterial respiration.  This non-radioactive compound, Tris 4,7-diphenyl-1,10-
phenanthroline ruthenium chloride pentahydrate, is inlaid in a rubber matrix at the bottom of the
media test tube.  Mycobacterial growth may also be determined as the result of turbidity in the
MGIT vial.  The basic media consists of Middlebrook 7H9 broth, casein peptone, glycerol, and
5% CO2.  The MGIT growth media was supplemented with the same substances as the Bactec
media excluding the egg yolk.  The aseptically inoculated MGIT tubes were evaluated for
bacterial growth approximately six weeks from the date of inoculation after incubation in the
same 5% CO2 incubator at 37o C (64, 6, 55).
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Figure 2.  Photograph and Schematic Diagram of the Bactec 460 TB Analyzer.
(A) Photograph of Bactec System in Biomolecular Building, Room 221.







Once a maximum growth reading of 999 using the Bactec system or visible turbidity using the
MGIT system was determined in a particular culture, the sample was then subcultured on solid
media in an attempt to isolate and visualize the morphology of specific mycobacterial colonies.
After thorough vortexing of the sample to be subcultured, a sterile loop was used to aseptically
transfer the positive culture broth onto a Mycobactosel L-J Medium Slant (Becton-Dicki son)
with the following formula of  reagents dissolved in 600 mL of purified H20:  2.5 g
Monopotassium Phosphate, 0.24 g Magnesium Sulfate, 0.6 g Sodium Citrate, 3.6 g L-
Asparagine, 30.0 g potato flour, 0.4  Malachite Green, 0.64 g Cycloheximide, 0.0032 g
Lincomycin, 0.056 g Nalidixic Acid, 12 mL Glycerol, and 1000.0 Whole Egg.  The slants were
then supplemented with 100 uL of Mycobactin J (2mg/L) to promote the growth of siderophore-
dependent Mycobacterium species.  The subcultures were stored at room temperature for 6-8
weeks or until detectable colonies appeared, after which the bacteria were harvested for analysis.
 Genomic DNA Extraction  
All MGIT, Bactec, and subcultured samples that showed positive growth were subjected to
genomic DNA extraction by the boil method using Phase-Lock Gel tubes.  After vortexing, a 100
uL portion of each sample was removed aseptically with a sterile syringe or loop and place  into
a clean 1.5 eppendorf microcentrifuge tube.  Each tube was then centrifuged at 14,000 rpm for 10
minutes at 4o C.  The supernatant was discarded, and the pellet was resuspended in 100 uL of TE
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buffer (10 mM Tris and 1 mM EDTA, pH 8.0 HCL).   The samples were boiled for 30 minutes at
100o C in a dry heat bath followed by an immediate 15 minute ice bath at 4o C. After
centrifugation of each sample at 12,000 rpm for 10 minutes at 4o C, the supernatant was
transferred to a prepared Phase-Lock Gel tube containing 200 uL of
phenol/chloroform/isoamylalcohol.  The aqueous sample and organic solution in the Phase-Lock
Gel tube were mixed thoroughly without vortexing until a homogeneous suspension was
achieved.  The Phase-Lock Gel tubes were then centrifuged at 12,000 rpm for 5 minutes at 4o C,
after which the upper aqueous phase containing the genomic DNA was transferred into a new 1.5
mL eppendorf microcentrifuge tube.  The samples were incubated overnight at -20o C in 200 mL
of cold 100% ethanol.  Following precipitation, the samples were again centrifuged at 14,000
rpm for 20 minutes at 4o C.  After the 100% ethanol was pipetted off and discarded, the DNA
pellet was washed with 400 uL of 80% ethanol; the tubes were re-centrifuged at 14,000 rpm for
an additional 20 minutes at 4o C.  Finally, the 80% ethanol was removed, and the DNA pellet was
dried in a DNA speed vacuum for 5 minutes and re-constituted in 50 mL of sterile, filtered qH2O.
Each extract was stored at -20o C. (64, 55)
 PCR Analysis  
 The Oligonucleotide Primers
Each DNA extract was evaluated by a PCR panel in order to detect and distinguish between
Mycobacterium avium subspecies:  avium, paratuberculosis, and intracellulare.  Oligonucleotide
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primers A-16-R (5'-ACCAGAAGACATGCGTCTTG-3') and A-16-L
(5'-AGAGTTTGATCCTGGCTCAG-3') specific for the amplification of the 193 base pair 16S
rRNA internal spacer region were used to detect the presence of subspecies avium and
paratuberculosis.  Primers MAC-R (5'-AGGTGGCGTCGAGGAAGAC-3') and MAC-L
(5'-GCCGCCGAAACGATCTAC-3') were used to identify the 427 base pair insertional
sequence 1245 indicative of the MAC which contains all of the above mentioned subspecies.
Two specific primers P90 (5'-GTTCGGGGCCGTCGCTTAGG-3') and P91
(5'GAGGTCGATCGCCCACGTGA-3') were employed as part of a PCR duplex reaction to
determine the presence of the 401 base pair insertional sequence 900 array specific to the
paratuberculosis genome.  The second round of DNA amplification required primers Av1
(5'-ATGTGGTTGCTGTGTTGGATGG-3') and Av2 (5'-CCGCCGCAATCAACTCCAG-3') to
increase the copy number of a 298 base pair internal region of the IS900 paratuberculosis
sequence.  All oligonucleotide primers used in this study were sequenced by Qiagen.  Lypholized
primers were dissolved in 100 uL of sterile TE buffer (10mM Tris and 0.1 mM EDTA, pH 7).
Table 1 summarizes all of the oligonucleotide primer sequences utilized in this study (64, 6, 55,
21).
 Optimization of the PCR Condition 
The amplification of each desired target sequence, including the 16S rRNA, IS1245, and IS900
regions, was optimized by following a series of crucial steps to achieve the highest possible
number of amplicons.  The process began by calculating the best temperatures at which to anneal
the primers to complementary genomic DNA sequences.  This was done by computing the
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melting temperatures from which the annealing temperatures were determined, usig the
following two equations:  Tm = [(#A + T) x 2oC] + [(#G + C) x 4oC] and Ta = Tm – 5oC.  Next,
the number and time of extension cycles were estimated based upon the length of the fragment
being copied (76).  Finally, the optimal PCR reagent concentrations along with the DNA
template amounts were deduced by a battery of trial and error experiments.  The specific PCR
reaction ingredients that were scrutinized include, oligonucleotide primers, Taq DNA
polymerase, as well as, DNA co-solvents MgCl2 and betaine.  Due to the similar nucleotide
content of each primer set and length of the target fragments, one protocol allowed maximu
detection for each desired sequence.  
 PCR Controls
All PCR experiments included two negative controls of sterile TE buffer (10 mM Tris and 0.1
mM EDTA, pH 8) to certify the absence of contamination in both the PCR reactions and the
genomic DNA extraction process.  Appropriate positive controls were also used for sample
comparison that included extracted avium and paratuberculosis subspecies DNA.  Positive
control DNA and PCR reactions were extracted and prepared separately to avoid contaminating
the study samples.
 Agarose Gel Electrophoresis Analysis  
Once amplification was completed, the individual PCR products were visualized by
electrophoresis.  The expected fragment sizes from the four PCR assays ranged from 193 bp to
427 bp (see Table 1); therefore, a 2% g/v agarose gel containing 0.5 ug/mL ethidium bromide
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dissolved in TE buffer (0.089 M Tris, 0.089 M boric acid, 0.002 M EDTA) was used for
analysis.  Specifically, 3 grams of agarose (Fisher Scientific) was added to 150 mL of TE buffer
and heated in the microwave until completely dissolved.  The mixture was then incubated in a
water bath at 56o C for 20 minutes.  Afterwards, a 3 uL volume of ethidium bromide was
thoroughly mixed into the agarose solution before it was poured into a tray.  The gel was allowed
to incubate at room temperature for 30 minutes until completely polymerized.  A 1.5 uL aliquot
of 6x Blue/Orange Loading Dye containing glycerol and sucrose (Promega) was pipetted into a
20 uL volume of each PCR product and mixed.  An additional 1.5 uL of loading dye was added
to 4 uL of 100 bp DNA Step Ladder (Promega) or Low Mass DNA Ladder (Invitrogen) for
fragment size comparison.  The gel was then loaded with  21.5 uL of each DNA/dye mixture and
5.5 uL of the reference DNA/dye mixture.  Electrophoresis analysis was performed at 120 volts
for 30-40 minutes, and the resulting gel was documented and photographed using the Gel-Dock
System (Biorad).
 Microscopic Analysis   
All subcultured samples and selected MGIT and Bactec cultures suspected of microbial growth
were analyzed for the presence of mycobacteria by using the Ziehl-Neelsen method (Difco).  The
surface of each slant was gently scraped with a sterile loop and the residue placed in a 250 uL
volume of qH2O.  A 50 uL aliquot of each microbial culture was then smeared onto a clean
microscope slide and allowed to air dry.  Once completely dry, the slides were quickly heat fixed
over an open flame and cooled to room temperature.  The slides were flooded with carbol-fushin
for 10 minutes while exposed to a steam bath to allow maximum penetration of dye into the
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bacterial cell wall.  They were then rinsed with a continuous stream of acid alcohol reagent for 30
seconds followed by a distilled water wash.  Malachite green was used as a counterstain to cover
the slides for 1 minute before a final distilled water rinse.  Afterward, the glass s ides were gently
blotted with bilbous paper and air dried prior to microscopic analysis. (64, 55) Slides displaying
acid-fast positive bacteria were then photographed as the example in Figure 5 Illustrates.
 DNA Purification  
PCR products that yielded positive results for the presence of MAP after amplification using Av1
and Av2 primers were directly purified using the Wizard PCR preps DNA Purification System
(Promega).   This process was necessary for later DNA sequencing.  According to this pr tocol,
the P90 and P91 products that corresponded to positive Av1 and Av2 samples were amplified in
duplicate until at least 30-300 uL of PCR reaction was obtained.  The PCR product was then
combined into one tube to which an aliquot of 100 uL of direct PCR purification buffer was
added.  The tube was thoroughly mixed.  One mL of resin was combined with the PCR
product/buffer solution and briefly vortexed three times over a one minute interval.  A Wizard
mini-column was prepared for each sample to be purified by removing the plunger from a 3 mL
Luer-Lok syringe (Becton-Dickinson) and attaching a mini-column to the syringe barrel.  The
resin/DNA mixture was transferred from the tube into the syringe, and the slurry was gently
pushed into the mini-column after insertion of the plunger into the syringe barrel.  A fresh barel
was attached to the mini-column to which 2 mL of 80% isopropanol was added.  The wash
solution was slowly driven through the mini-column again with the original plunger.  The syringe
barrel was removed, and the mini-column was centrifuged in a 1.5 mL microcentrifuge tube at
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12,000 rpm for 2 minutes at 4o C.  The purified DNA was eluted into a fresh 1.5 mL
microcentrifuge tube by pipetting 50 uL of sterile TE buffer directly onto the mini-column.  After
one full minute, the purified DNA was collected when the mini-column/microcentrifuge tube
combination was centrifuged at 12,000 rpm for 20 seconds at room temperature.  The mini-
column was then discarded, and the DNA stored at –20o C until time of sequencing.
 DNA  Quantification  
Following purification, the IS900 DNA amplicons were quantified using the DNA Dipstick Kit
(Invitrogen) prior to being sent for sequencing.  In house analysis revealed that the DNA Dipstick
Kit results were comparable to spectrophotometer readings.  The quantification procedure began
by spotting 1 uL of purified DNA onto the dipstick membrane where it was allowed to
completely air dry.  The DNA dipstick containing the dry sample was then placed for 10 second
into a provided cuvette containing 1 mL of wash solution.  Next, the DNA dipstick was
transferred to a second cuvette for 3 minutes which held 1 mL of coupling solution.  The DNA
dipstick was removed from the second cuvette and rinsed with deionized water for 20 seconds
followed by a 4 minute incubation in the wash solution.  A third cuvette was prepared that
contained a solution of 1 mL developer stock and 1 drop of developer.  The DNA dipstick was
placed in the developer for 2 minutes and then gently rinsed in wash solution for 20 seconds.
Finally, the DNA dipstick was laid flat, membrane face-up, to air dry.  Once completely dry, the
sample spot on the DNA dipstick membrane was compared to the color intensities of the control
DNA spots on the standard chart reference card provided by the DNA Dipstick kit.  The control
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spots ranged in concentration from 0.1 ng/uL to 10 ng/uL; the sample concentrations were
estimated based upon their closeness in color to the standard spots.
 DNA Sequencing and Analysis  
 The PCR product containing the target DNA amplicon, a 298 base-pair internal region of the
IS900 gene, resulted from a nested PCR assay (P90, P91 & Av1, Av2 primer sets).  Figure 3
illustrates the amplified regions of the IS900 gene following nested PCR using the above
mentioned primers.  Once the required 30-300 uL volume of PCR product was obtained, it was
purified directly by the Wizard PCR Preps DNA Purification System (Qiagen) previously
described.  The presence of the purified IS900 product was confirmed by agarose gel
electrophoresis and quantified via the DNA dipstick and Low Mass DNA marker (Invitrogen).
DNA sequencing of the different purified IS900 fragments was performed at the DNA
Sequencing Core Facility in the Department of Molecular Biology and Microbiology at the
University of Central Florida using the Av1 oligonucleotide primer sequence (Table 1).  Raw
nucleotide sequence data was analyzed using computer facilities at the University of Central
Florida able to access the National Center for Biotechnology Information (NCBI) website
(http://www.ncbi.nlm.nih.gov/).  This particular internet site employs the Entrez search engine
which can retrieve and compare data from many different databases that include such
information as nucleotide sequences, protein sequences, whole genomes, macromolecular
structures, and MEDLINE.  The IS900 sequences acquired in this study were entered into the
BLAST program, a comparative analysis tool provided via the world wide web, where they were
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scrutinized against sequences in the NIH genetic sequence database also known as GenBank.
(56)
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Figure 3.  Illustration of Amplified Regions of the IS900 Gene following Nested PCR using




 Optimization  
The initial focus of preliminary experiments was to detect MAC species/subspecie  by choosing
a set of oligonucleotide primers that would provide optimal product selectivity, sensitivity, and
yield.  Originally, a primer set named Av22a/Av22b was chosen that targeted a 91 bp fragment
common to all MAC bacteria (kindly provided by F.A.K. El-Zaatari, Baylor College of
Medicine).  Many attempts were made to amplify this fragment in positive controls by
conducting serial dilution trails that varied the concentrations of MgCl2 and/or MgSO4, DNA Taq
polymerase, primers, and template.  After exhausting all variables when using Av22a/Av22b
PCR including these primers had poor success as Figure 4 illustrates.  Consequently, more
experiments were designed in order to determine why little progress was made in earlier
optimization steps.  This included re-evaluation of the selected primers with regard to several
design criteria such as sequence content, nucleotide length, and melting and annealing
temperatures.  Surprisingly, it was discovered that the Av22a/Av22b primer set had a 10oC
difference between their melting and annealing temperatures.  Normally, for primers to work
optimally, their annealing temperatures need to be within ~2-4oC of each other.  Therefore, the
next focus of the optimization process was to find primers for MAC that met standard design
criteria, especially annealing temperature.  Following an extensive literatur  search, several sets
of primers were chosen that could detect and distinguish specific MAC subspecies.  To continue
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the optimization process, the 70 kDa heat shock protein (hspx) characteristic of MAP was
targeted.  The MAP h-L/MAP h-R oligonucleotide primer set, which are 19 and 18 base pairs
respectively, amplify a 211 bp fragment.  Again, many experiments were designed that varied the
PCR reagents and thermocycler conditions.  Specifically, it was the concentration of
oligonucleotide primers that had the greatest impact on hspx DNA amplification.  When the
primers, having an original concentration of 10uM, were diluted in a 1:50 solution of primer to
TE buffer (10mM Tris, 0.1mM EDTA, pH 7.0), PCR specificity was greatly improved.
Similarly, different Mg concentrations also influenced fragment amplification and became a
critical factor in optimizing PCR specificity.  High amounts of Mg favored prime -dimer
formation and increased non-specific product yield, while low amounts decreased the level of
desired product.  For example, Figure 5 illustrates the results of the hspx PCR assay in which the
concentrations of oligonucleotide primers and MgCl2 were varied.  Lane 15 contained 10 pmoles
of undiluted primers and 0.1 umoles of MgCl2 and shows a faint 211 bp DNA band indicating the
presence of the hspx gene.  Lanes 17 and 19 contained the same level of primers (10 pmoles) and
increased amounts of MgCl2 (0.3 umoles & 0.4 umoles, respectively) and show no detection of
the hspx in positive control samples.  These relatively high levels of primer and Mg produced
large dimers which interfered with the detection of the 211 bp hspx fragment.  On the other hand,
lanes 9, 11, and 13 show clear positive results for the 211 bp hspx fragment, whereby the MgCl2
level was at a constant 0.2 umoles amount and the primer quantities were 0.2 pmoles , 0.4
pmoles, and 0.8 pmoles, respectively.  Consequently, lane 11 showed optimal amplification of
the 211 bp hspx fragment with little dimer formation; this occurred when primer amounts were
relatively low (0.4 pmoles) and MgCl2 were high (0.4 umoles).   
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Figure 4.  Early PCR Optimization Results using Av22a/Av22b oligonucleotide primers for the
detection of MAC.
M corresponds to a 1 Kb 100 base pair DNA step ladder.  (A) shows an agarose gel that
corresponds to an experiment in which the PCR reaction contained 5 pmoles of each primer, 0.15
umoles of MgCl2, 1.75 units of DNA Taq Polymerase Sequencing Grade and 5 uL of MAP
template.  The number of amplification cycles in the thermocycler were varied in 7 cycle
intervals for lanes 1, 2, 3, 4 & 5.  Lane 5 shows a faint 91 bp fragment indicating the presence of
MAC DNA.  (B) shows an agarose gel that corresponds to an experiment in which the PCR
reaction contained 5 pmoles of each primer, 1.75 units of DNA Taq Polymerase Sequencing
Grade, 5 uL of MAP template, and varying amounts of MgCl2.  Lanes 4 & 5 contained 0.1
umoles & 0.3 umoles of MgCl2, respectively, and show faint 91 bp fragments indicating the
presence of MAC DNA.  
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Figure 5.  Optimization of MgCl2 versus Oligonucleotide Primer Concentrations in Hspx PCR
Assay.
M corresponds to a 1 Kb 100 bp DNA step ladder.  Lanes 1 & 2 correspond to negative controls.
Lanes 3 & 4 correspond to a PCR reaction containing 10 pmoles of each primer and 0.2 umoles
MgCl2.  Lane 6 contains 0.2 pmoles of each primer and 0.2 umoles MgCl2.  Lane 7 contains 0.4
pmoles of each primer and 0.2 umoles MgCl2.  Lane 8 contains 0.8 pmoles of each primer and
0.2 umoles MgCl2.  Lane 9 contains 10 pmoles of each primer and 0.1 umoles MgCl2.  Lane 10
contains 10 pmoles of each primer and 0.3 umoles MgCl2.  Lane 11 contains the same reagent
concentrations as lanes 3 & 4, except it has 1.25 units of DNA Taq Polymerase instead of 5 units
like all the other reactions.  Lanes 6, 7, 8, & 9 show 211 bp DNA fragments indicative of the
hspx specific to MAP.
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Several experiments were performed using different types of DNA Taq polymerase in order to
determine which one would provide optimal sensitivity as well as allow for a time effective
thermocycler protocol.  Red Taq Polymerase (Sigma) was tried early in the optimization process
with little success (no data shown).  DNA Taq Polymerase Sequencing Grade did yield moderate
sensitivity yet required extensive cycling conditions.  Finally, Platinum Hi-Fidelity DNA Taq
Polymerase (Invitrogen), as opposed to others tried, increased the clarity and intensity of DNA
fragments while reducing the time needed for amplification.  Figure 6 shows a comparison of
DNA Taq Polymerase Sequencing Grade and Platinum Hi-Fidelity DNA Taq Polymerase and
thermocycling protocols in which they worked best.  The amount of template was also modified
in order to allow for sensitivity of low DNA copy number without incurring detection
interference.  Extracted DNA concentrations varied considerably, consequently, a large mount
of template (10 uL) was used in each PCR reaction.  Knowing the high G+C content in
mycobacteria, the DNA co-solvent betaine was explored as an alternative to DMSOto further
optimize the sensitivity of the PCR assays by minimizing secondary structure formation, thereby
enhancing primer annealing.  Experimental results demonstrated that 25.5 umoles of betaine was
the optimum amount required in the PCR reaction mixture to yield the greatest fragment
amplification (Figure 8).
Throughout the optimization process, the thermocycler conditions were refined for optimal
selectivity and sensitivity based upon the the calculated annealing temperatures of he primers as
well as the length of the desired PCR product.  Table 1 provides an overview of all relevant
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information related to primer selections and optimization, particularly melting and annealing
temperatures.  
Table 1: Primer Selections for PCR Panel to Detect and Distinguish Members of MAC
MAC ss ss. loci PCRproduct
Primer








193 bp A-16-L 5'-AGAGTTTGATCCTGGCTCAG-3' 58 53
A-16-R 5'-ACCAGAAGACATGCGTCTTG-3' 58 53
** M. Avium
Complex
IS1245 427 bp MAC-L 5'-GCCGCCGAAACGATCTAC-3' 58 53
MAC-R 5'-AGGTGGCGTCGAGGAAGAC-3' 62 57
MA para-
tuberculosis
IS900 401 bp P90 5'-GTTCGGGGCCGTCGCTTAGG-3' 67 62
P91 5'-GAGGTCGATCGCCCACGTGA-3' 65 60
MA para-
tuberculosis




AV2 5'-CCGCCGCAATCAACTCCAG-3' 62 57
A MA para-
tuberculosis
Hspx 211bp Map h-L 5'-GACCGGCTATCTGTGGAAC-3' 60 55
Map h-R 5'-CTCGTCGGCTTGCACCTG-3' 61 56
B ***M. Avium
Complex
-- 91 bp Av22a 5'-CGCCGGAAAACGCCGTG-3' 60 55
 Av22b 5'-CGTAACACGAAGACGTA-3'' 50 45
*M. Avium Complex includes MAV and MAP; ** M. Avium Complex  includes MAV and MI (more typing necessary due to limited strain
detection in MI); ***M. Avium Complex includes MAV, MI, and MAP
AHspx Assay discontinued due to poor success in samples (low copy number)
B Assay discontinued due to poor success in samples (10oC in annealing temperatures)
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Figure 6.  PCR Optimization of Different DNA Taq Polymerases versus Thermocycling
Conditions in the Detection of MAP using P90/P91 primer set.
(A) shows an agarose gel that corresponds to an experiment in which DNA Taq Polymerase
Sequencing Grade was used with thermocycling conditions as follows:  an initial 5 minute hot
start at 94oC and 39 cycles of:  1 minute denaturation at 94oC, 1 minute primer annealing at 58oC,
and 3 minutes extension at 72oC.   M corresponds to a 1 Kb 100 bp DNA step ladder.  Lanes 1 &
2 show bands for the 401 bp fragment of IS900 after the first round of nested PCR using 10 uL of
MAP template (Kay & Linda DNA, respectively).  (B) shows an agarose gel that corresponds to
an experiment in which Platinum Hi-Fidelity DNA Taq Polymerase and DNA Taq Polymerase
Sequencing Grade were compared and used with thermocycler conditions as follows:  an initial 5
minute hot start at 94oC and 30 cycles of:  45 second denaturation at 94oC, 30 primer annealing at
56oC, and 2 minutes extension at 72oC.  M corresponds to a Low Density 100 base pair DNA
step Ladder.  Lane 1 contains DNA Taq Polymerase Sequencing Grade and shows no visible
band, while Lane 2 contains the Platinum Hi-Fidelity DNA Taq Polymerase and shows a 401 bp
fragment for the IS900 gene indicating MAP (4 uL load onto gel).  Lanes 3 & 4 show the same
samples respectively (20 uL load onto gel).
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Additionally, the optimal PCR reaction cocktail mixture was identified which encompassed a
common PCR reaction mixture that positively amplified all previously mentioned DNA
fragments that indicate the presence of Mycobacterium avium subspecies.  The optimal PCR
reaction included 17 uL of sterile H2O, 5 uL of 10x Hi-Fi buffer (Invitrogen), 8.5 uL of 3 M
betaine, 1 uL of 10 mM dNTP's (Fisher Scientific), 4 uL of 50 mM MgSO4 (Invitrogen), 2 uL
each of 10 mM specific oligonucleotide primer, and 0.5 uL of 100 unit Platinum Hi-Fi Taq
polymerase (Invitrogen).  The total volume of the PCR reaction was brought to 50 uL by the
addition of 10 uL of template DNA from each extracted sample.  The individual PCR reactions
were then placed into a thermocycler (Biorad) with programmed conditions that allowed  the
amplification of all mentioned DNA fragments depending upon on the added primers.
The program began with a 5 minute hot start to ensure full DNA denaturation followed by 30
cycles of the following steps:  denaturation at 94o C for 45 seconds, primer annealing at 56o C for
30 seconds, and extension at 72o C for 2 minutes.  The thermocycler protocol ended with a final
72o C extension for 10 minutes followed by a 4o C  indefinite hold.  Figures 7I and 7II illustrate
the progression of PCR conditions within the thermocycler as well as the final concentration of
specific reagents used in the PCR reaction before and after the final  optimization.  Finally,
Figure 8 shows a comparison of the early optimization versus final optimization results for all
three PCR assays used in this study.
Once a practical protocol for optimal amplification of desired products was developed, it was
applied to DNA samples obtained from the gut tissue of 100 test subjects.  Specifically, these
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three PCR assays used in this investigation were performed on all DNA obtained from cultured
mycobacterial isolates.
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Figure 7-I.  Thermocycler Protocols and PCR Reagent Concentrations after Optimization.
(A) shows the final thermocycler conditions upon optimization completion.




Sterile H20 17 uL
10x Hi-Fi Buffer 5 uL
3 M Betaine 8.5 uL
10 mM dNTP Mix 1 uL
50 mM MgSO4 4 uL
10 uM Primer (1:50 dilution) 2 uL (each)
100 u Platinum Hi-Fi DNA Taq Polymerase 0.5 uL
Template DNA 10 uL
Total Volume 50 uL
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Figure 7-II.  Thermocycler Protocols and PCR Reagent Concentrations before  Optimization.
(A) shows the preliminary thermocycler conditions before optimization completion.  




Sterile H20 31.75 uL
10x Buffer w/ MgCl2 5 uL
DMSO 5 uL
10 uM Primer (1:50 dilution) 1 uL (each)
10 mM dNTP Mix 1 uL
100 u DNA Taq Polymerase Sequencing Grade 0.25 uL
Template DNA 5 uL
Total Volume 50 uL
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Figure 8.  Comparison of Early Optimization Trials versus Final Optimization Trials for all PCR
Assays used in this Study.
(A) shows a primer test using DNA Taq Polymerase Sequencing Grade used with thermocycler
conditions before optimization (use of DMSO).  M corresponds to a 1Kb 100 bp DNA step
ladder.  Lane 1=negative control (IS900; MAP), Lane 2=negative control (Hspx; MAP), Lane
3=negative control (IS1245; MAV), Lane 4=negative control (16 S rRNA; MAV), Lane
5=positive control (IS900; MAP; no visible 401 bp fragment), Lane 6=positive control (Hspx;
MAP; 211 bp), Lane 7=positive control (IS1245; MAV; no visible 427 bp fragment), Lane
8=positive control (16 S rRNA; MAP; 193 bp), Lane 9=positive control (16 S rRNA;MAV; 193
bp).  (B) shows a primer test using Platinum Hi-Fidelity DNA Taq Polymerase with thermocycler
conditions after optimization (use of betaine).  M corresponds to a 1Kb 100 bp DNA step ladder.
Lane=negative control (IS1245), Lane 2=positive control (IS1245; MAV; 427 bp), Lane
3=negative control (16 S rRNA), Lane 4=positive control (16 S rRNA; MAV; 193 bp), Lane
5=negative control (16 S rRNA), Lane 6=positive control (16 S rRNA; MAP; 193 bp), Lane
7=negative control (Hspx), Lane 8=positive control (Hspx; MAP; 211 bp), Lane 9=negative
control (IS900; 1st amplification), Lane 10=positive control (IS900; MAP; 401 bp; 1st
amplification), Lane 11=negative control (IS900; 2nd amplification), Lane 12=positive control
(IS900; MAP; 298 bp, 2nd amplification)
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 Specimen Processing  
A total of 100 resected, full-thickness tissue samples removed from IBD patients were received
from Mt. Sinai Hospital and included in this two year etiological study.  Table 2 details the code
as well as dates of collection and processing.
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Table 2: Tissue Processing and Growth Time in Bactec Media
ACode Collection Date Process Date Maximum GI Date BDuration
MS8 11/07/01 11/08/01 12/03/01 25
MS8e 11/07/01 11/08/01 12/03/01 25
MS11 11/08/01 11/09/01 12/03/01 24
MS11e 11/08/01 11/09/01 12/03/01 24
MS12 11/14/01 11/15/01 12/03/01 18
MS12e 11/14/01 11/15/01 12/03/01 18
MS13e 11/14/01 11/15/01 12/03/01 18
MS19e 11/16/01 11/17/01 12/03/01 16
MS21 11/20/01 11/21/01 12/03/01 12
MS21e 11/20/01 11/21/01 12/07/01 16
MS22 11/20/01 11/21/01 12/07/01 16
MS22e 11/20/01 11/21/01 12/07/01 16
MS24e 11/20/01 11/21/01 12/07/01 16
MS25 11/27/01 11/28/01 12/26/01 28
MS25e 11/27/01 11/28/01 12/11/01 13
MS29 11/29/01 11/30/01 12/11/01 11
MS30 11/29/01 11/30/01 12/11/01 11
MS32 12/04/01 12/05/01 12/26/01 21
MS41e 12/14/01 12/15/01 01/02/02 18
MS47 01/09/02 01/10/02 01/22/02 12
MS62e 01/30/02 01/31/02 02/25/02 25
MS67 02/04/02 02/05/02 02/25/02 20
MS68 02/04/02 02/05/02 02/25/02 20
MS71 02/05/02 02/06/02 02/25/02 19
MS71e 02/05/02 02/06/02 03/11/02 34
MS83 02/12/02 02/13/02 03/11/02 27
MS92 03/04/02 03/05/02 04/09/02 35
MS92e 03/04/02 03/05/02 04/09/02 35
A Refers to codes blindly assigned to tissue samples; B Refers to duration of bacterial growth in days
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Once prepared, the individual tissue specimens were inoculated into the Bactec and MGIT
culture systems.  Two Bactec media bottles were used for each sample and contained nutrients
and supplements previously described; one of the bottles included the addition of egg yolk.
Consequently, a total of 200 Bactec samples were used for this project.  Accordingly, one MGIT
culture tube was inoculated from each processed tissue, for a total of 100 MGIT culture
specimens.  Tables 3, 4, and 5 outline the type of media used for each sample.
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Table 3: Documentation of Received IBD Tissues  and Media Types Used for Samples 1-37
ACode Collection Date Date Received
         Media Type
B+E B-E MGIT
1 10/25/01 10/26/01 ✔ ✔ ✔
2 10/26/01 10/27/01 ✔ ✔ ✔
3 10/30/01 10/31/01 ✔ ✔ ✔
4 10/31/01 11/01/01 ✔ ✔ ✔
5 10/31/01 11/01/01 ✔ ✔ ✔
6 10/31/01 11/01/01 ✔ ✔ ✔
7 11/01/01 11/02/01 ✔ ✔ ✔
8 11/07/01 11/08/01 ✔ ✔ ✔
9 11/08/01 11/09/01 ✔ ✔ ✔
10 11/08/01 11/09/01 ✔ ✔ ✔
11 11/08/01 11/09/01 ✔ ✔ ✔
12 11/14/01 11/15/01 ✔ ✔ ✔
13 11/14/01 11/15/01 ✔ ✔ ✔
14 11/14/01 11/15/01 ✔ ✔ ✔
15 11/15/01 11/16/01 ✔ ✔ ✔
16 11/16/01 11/17/01 ✔ ✔ ✔
17 11/16/01 11/17/01 ✔ ✔ ✔
18 11/16/01 11/17/01 ✔ ✔ ✔
19 11/16/01 11/17/01 ✔ ✔ ✔
20 11/20/01 11/21/01 ✔ ✔ ✔
21 11/20/01 11/21/01 ✔ ✔ ✔
22 11/20/01 11/21/01 ✔ ✔ ✔
23 11/20/01 11/21/01 ✔ ✔ ✔
24 11/20/01 11/21/01 ✔ ✔ ✔
25 11/27/01 11/28/01 ✔ ✔ ✔
26 11/28/01 11/29/01 ✔ ✔ ✔
27 11/28/01 11/29/01 ✔ ✔ ✔
28 11/29/01 11/30/01 ✔ ✔ ✔
29 11/29/01 11/30/01 ✔ ✔ ✔
30 11/29/01 11/30/01 ✔ ✔ ✔
31 12/03/01 12/04/01 ✔ ✔ ✔
32 12/04/01 12/05/01 ✔ ✔ ✔
33 12/05/01 12/06/01 ✔ ✔ ✔
34 12/06/01 12/07/01 ✔ ✔ ✔
35 12/06/01 12/07/01 ✔ ✔ ✔
36 12/06/01 12/07/01 ✔ ✔ ✔
37 12/10/01 12/11/01 ✔ ✔ ✔
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Table 4: Documentation of Received IBD Tissues and Media Types Used for Samples 38-74
ACode Collection Date Date Received
         Media Type
B+E B-E MGIT
38 12/10/01 12/11/01 ✔ ✔ ✔
39 12/11/01 12/12/01 ✔ ✔ ✔
40 12/11/01 12/12/01 ✔ ✔ ✔
41 12/14/01 12/15/01 ✔ ✔ ✔
42 12/14/01 12/15/01 ✔ ✔ ✔
43 12/14/01 12/15/01 ✔ ✔ ✔
44 01/08/02 01/09/02 ✔ ✔ ✔
45 01/08/02 01/09/02 ✔ ✔ ✔
46 01/09/02 01/10/02 ✔ ✔ ✔
47 01/09/02 01/10/02 ✔ ✔ ✔
48 01/09/02 01/10/02 ✔ ✔ ✔
49 01/10/02 01/11/02 ✔ ✔ ✔
50 01/10/02 01/11/02 ✔ ✔ ✔
51 01/15/02 01/16/02 ✔ ✔ ✔
52 01/15/02 01/16/02 ✔ ✔ ✔
53 01/15/02 01/16/02 ✔ ✔ ✔
54 01/17/02 01/18/02 ✔ ✔ ✔
55 01/17/02 01/18/02 ✔ ✔ ✔
56 01/17/02 01/18/02 ✔ ✔ ✔
57 01/22/02 01/23/02 ✔ ✔ ✔
58 01/23/02 01/24/02 ✔ ✔ ✔
59 01/28/02 01/29/02 ✔ ✔ ✔
60 01/29/02 01/30/02 ✔ ✔ ✔
61 01/29/02 01/30/02 ✔ ✔ ✔
62 01/30/02 01/31/02 ✔ ✔ ✔
63 01/30/02 01/31/02 ✔ ✔ ✔
64 01/31/02 02/01/02 ✔ ✔ ✔
65 02/04/02 02/05/02 ✔ ✔ ✔
66 02/04/02 02/05/02 ✔ ✔ ✔
67 02/04/02 02/05/02 ✔ ✔ ✔
68 02/04/02 02/05/02 ✔ ✔ ✔
69 02/05/02 02/06/02 ✔ ✔ ✔
70 02/05/02 02/06/02 ✔ ✔ ✔
71 02/05/02 02/06/02 ✔ ✔ ✔
72 02/05/02 02/06/02 ✔ ✔ ✔
73 02/07/02 02/08/02 ✔ ✔ ✔
74 02/07/02 02/08/02 ✔ ✔ ✔
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Table 5: Documentation of Received IBD Tissues and Media Types Used for Samples 75-100
ACode Collection Date Date Received
         Media Type
B+E B-E MGIT
75 02/07/02 02/08/02 ✔ ✔ ✔
76 02/07/02 02/08/02 ✔ ✔ ✔
77 02/07/02 02/08/02 ✔ ✔ ✔
78 02/07/02 02/08/02 ✔ ✔ ✔
79 02/07/02 02/08/02 ✔ ✔ ✔
80 02/11/02 02/12/02 ✔ ✔ ✔
81 02/11/02 02/12/02 ✔ ✔ ✔
82 02/12/02 02/13/02 ✔ ✔ ✔
83 02/12/02 02/13/02 ✔ ✔ ✔
84 02/14/02 02/15/02 ✔ ✔ ✔
85 02/14/02 02/15/02 ✔ ✔ ✔
86 02/19/02 02/20/02 ✔ ✔ ✔
87 02/19/02 02/20/02 ✔ ✔ ✔
88 02/19/02 02/20/02 ✔ ✔ ✔
89 02/20/02 02/21/02 ✔ ✔ ✔
90 02/20/02 02/21/02 ✔ ✔ ✔
91 02/27/02 02/28/02 ✔ ✔ ✔
92 03/04/02 03/05/02 ✔ ✔ ✔
93 03/04/02 03/05/02 ✔ ✔ ✔
94 03/05/02 03/06/02 ✔ ✔ ✔
95 03/05/02 03/06/02 ✔ ✔ ✔
96 03/19/02 03/20/02 ✔ ✔ ✔
97 03/19/02 03/20/02 ✔ ✔ ✔
98 03/21/02 03/22/02 ✔ ✔ ✔
99 03/21/02 03/22/02 ✔ ✔ ✔
100 04/11/02 04/12/02 ✔ ✔ ✔
Total Cultures 100 100 100
Total Bactec Cultures 200
A Refers to codes blindly assigned to tissue samples (Table 3-5)
 Mycobacterial   Growth in Bactec Media 
All Bactec bottles were evaluated for bacterial growth using the Bactec 460 TB system. Of the
200 Bactec cultures, 13 bottles containing egg yolk and 15 bottles without egg yolk reached a
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maximum growth index of 999.  In all, a total of 28 cultures, comprised of tissue samples from
20 IBD subjects,  produced bacterial growth using the Bactec media system.  Eight of those
individual tissue specimens exhibited bacterial growth in both types of Bactec culture media (+
egg yolk and – egg yolk supplement).  Ranging from 11 to 34 days of incubation at 37o C with
5% CO2, the 28 positive specimens took an average of 20.5 days to obtain a maximum growth
reading.  Table 2 (listed above) summarizes the list of samples that showed growth using the
Bactec system as well as the amount of time required to reach a GI of 999.  All Bactec bottles
with suspected mycobacteria growth were removed from the incubator and subjected to further
investigation as follows:  A volume of 0.5 mL of culture was aseptically transferred into a 1.5
mL eppendorf tube for genomic DNA extraction and subsequent PCR analysis.   An additional
50 uL aliquot of culture was used for Ziehl-Neelsen acid-fast staining.  Table 6 illustrates the
acid-fast status of each Bactec culture and/or subculture that demonstrated growth.  All 28
samples that gave a 999 reading were then evaluated by PCR assay using primers specific for the
16S rRNA internal spacer region. This 193 bp DNA fragment, indicative of  M. avium complex
(MAC), was detected in 26/28 (93%) of suspect Bactec cultures.  Table 1 (listed above)
references the specific MAC loci, expected PCR product size, and primer sequences for all PCR
assays used in this study.  
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Table 6: Acid-fast Results on Bactec Cultures and Subcultures





























+:  was determined to be positive in both cultures and subcultures
*: staining was done only on subcultures.
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A representative set of these 16S rRNA results is shown in Figure 9.Only sample MS71 did not
exhibit the presence of the 193 bp PCR product, indicating the absence of MAC DNA. However,
unlike sample 71, acid-fast revealed that culture 71e contained acid-fast bacteria. Table 7
categorizes samples contain MAC DNA based on the results of the 16S rRNA.   
Table 7: Results of the 16S rRNA PCR Assay on Positive Bactec Cultures
ACode BDuration 16S rRNA PCR result Conclusion
MS8 25 + MAC
MS8e 25 + MAC
MS11 24 + MAC
MS11e 24 + MAC
MS12 18 + MAC
MS12e 18 + MAC
MS13e 18 + MAC
MS19e 16 + MAC
MS21 12 + MAC
MS21e 16 + MAC
MS22 16 + MAC
MS22e 16 + MAC
MS24e 16 + MAC
MS25 28 + MAC
MS25e 13 + MAC
MS29 11 + MAC
MS30 11 + MAC
MS32 21 + MAC
MS41e 18 + MAC
MS47 12 + MAC
MS62e 25 + MAC
MS67 20 + MAC
MS68 20 + MAC
MS71 19 - Other than MAC
MS71e 34 - Other than MAC
MS83 27 + MAC
MS92 35 + MAC
MS92e 35 + MAC
A Refers to codes blindly assigned to tissue samples; B Refers to duration of bacterial growth in days
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Figure 9.  16 S rRNA PCR Assay Results for Representative Set of Bactec Cultures. 
M corresponds to a 1Kb 100 bp DNA step ladder.  Lanes 1 & 2=negative controls.  Lane 3=MS8,
Lane 4=MS8e, Lane 5=MS11e, Lane 6=12, Lane 7=MS12e, Lane 8=MS13e, Lane 9=19e, Lane
10=MS21, Lane 11=MS21e, Lane 12=MS22, Lane 13=MS22e, Lane 14=MS62e, Lane
15=MS67, Lane 16=MS68, Lane 17=MS71, Lane 18=positive control (MAV; 193 bp)
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Therefore, these results demonstrate the presence of MAC in 93% of harvested Bactec bottles.  In
order to identify the particular member of the MAC present in the positive Bactec cul ures,
further PCR analysis using IS1245 specific primers indicative of M. avium avium (MAV) was
performed.  The assay revealed that 25 Bactec tissue cultures (89%) tested positive for the 427 bp
IS1245 DNA fragment.  Figure 10 shows a representative set of these IS1245 assay results.
Additionally, Table 8 shows the results of the IS1245 PCR assay.  An additional nested PCR
assay was conducted to further determine the presence of M. avium paratuberculosis (MAP).
The first part of the assay detected a 401 bp portion of the IS900 insertional element not normally
visible after electrophoresis analysis because of low copy number.  In order for the IS900
fragment to be seen, the PCR product from the first assay was used as a template for the second
round of amplification.  Consequently, the resulting 298 bp fragment of the IS900 DNA
amplicon was only seen after a second round of PCR.  A total of 6 Bactec cultures (21%) showed
a positive result for the IS900 DNA sequence indicative of MAP.  Figure 11 illustrates a
representative set of the IS900 nested PCR results on Bactec cultures. Table  9 summarizes the
results of nested PCR on all positive Bactec bottles.  
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Figure 10.  IS1245 PCR Assay Results for Representative Set of Bactec Cultures.
M corresponds to a 1Kb 100 bp DNA step ladder.  Lanes 1 & 2=negative controls.  Lane 3=MS8,
Lane 4=MS8e, Lane 5=MS11, Lane 6=MS11e, Lane 7=MS12, Lane 8=MS12e, Lane 9=MS13e,
Lane 10=MS19e, Lane 11=MS21, Lane 12=MS21e, Lane 13=MS22, Lane 14=MS22e, Lane
15=MS24e, Lane 16=MS25, Lane 17=MS25e.  Lane 18=positive control (MAV; 427 bp).  Lane
19 shows no band and corresponds to positive control MAP DNA.
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Table 8: Results of the IS1245 PCR Assay on Positive Bactec Cultures
ACode BDuration IS1245 PCR result Conclusion
MS8 25 + MAV
MS8e 25 + MAV
MS11 24 + MAV
MS11e 24 + MAV
MS12 18 + MAV
MS12e 18 + MAV
MS13e 18 + MAV
MS19e 16 + MAV
MS21 12 + MAV
MS21e 16 + MAV
MS22 16 + MAV
MS22e 16 + MAV
MS24e 16 + MAV
MS25 28 + MAV
MS25e 13 + MAV
MS29 11 - MAC
MS30 11 + MAV
MS32 21 + MAV
MS41e 18 + MAV
MS47 12 + MAV
MS62e 25 + MAV
MS67 20 + MAV
MS68 20 + MAV
MS71 19 - Other than MAC*
MS71e 34 - Other than MAC*
MS83 27 + MAC
MS92 35 + MAC
MS92e 35 + MAC
A Refers to codes blindly assigned to tissue samples
B Refers to duration of bacterial growth in days
*Other than MAC conclusion based upon acid-fast staining morphology
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Table 9: Results of the IS900 Nested PCR Assay on Positive Bactec Cultures
 ACode BDuration IS900 nested PCR Conclusion
MS8 25 - MAV
MS8e 25 - MAV
MS11 24 + MAP
MS11e 24 + MAP
MS12 18 - MAV
MS12e 18 - MAV
MS13e 18 - MAV
MS19e 16 - MAV
MS21 12 - MAV
MS21e 16 - MAV
MS22 16 - MAV
MS22e 16 - MAV
MS24e 16 - MAV
MS25 28 - MAV
MS25e 13 - MAV
MS29 11 - MAC
MS30 11 + MAP
MS32 21 - MAV
MS41e 18 - MAV
MS47 12 - MAV
MS62e 25 - MAV
MS67 20 - MAV
MS68 20 - MAV
MS71 19 - Other than MAC
MS71e 34 + Other than MAC
MS83 27 - MAV
MS92 35 - MAV
MS92e 35 + MAP
A Refers to codes blindly assigned to tissue samples
B Refers to duration of bacterial growth in days
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Figure 11.  IS900 Nested PCR Assay Results for Representative Set of Bactec Cultures.
(A) corresponds to the 1st round of nested PCR using primers P90/P91.  (B) corresponds to the
2nd round of nested PCR using primers Av1/Av2.  M1 corresponds to a 1Kb 100 bp DNA step
ladder.  M2 corresponds to a 25 bp DNA step ladder.  Lane 1=positive control {MAP; 401 bp
(A); 298 bp (B), Lane 2=negative control,  Lane 3=MS11e,  Lane 4=MS11,  Lane 5=MS22e,
Lane 6=MS30,  Lane 7=MS71e.  The image of positive samples are from different agarose gels
visualized at different times.
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Overall, out of the 6 Bactec cultures confirmed to contain MAP, 5 (83%) showed  positive results
for all three assays:  16S rRNA, IS1245, and IS900 nested PCR.  Table 10 concludes the MAC
subspecies present in all 28 Bactec cultures based upon the overall PCR analysis.  
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Table 10: Summary of Three Assays on Bactec Cultures





MS8 25 + + - MAV
MS8e 25 + + - MAV
MS11 24 + + - MAV
MS11e 24 + + + MAP
MS12 18 + + + MAP
MS12e 18 + + - MAV
MS13e 18 + + - MAV
MS19e 16 + + - MAV
MS21 12 + + - MAV
MS21e 16 + + - MAV
MS22 16 + + - MAV
MS22e 16 + + + MAP
MS24e 16 + + - MAV
MS25 28 + + - MAV
MS25e 13 + + - MAV
MS29 11 + - - MAC
MS30 11 + + + MAP
MS32 21 + + - MAV
MS41e 18 + + - MAV
MS47 12 + + - MAV
MS62e 25 + + - MAV
MS67 20 + + - MAV
MS68 20 + + - MAV
MS71 19 - - - Other than MAC
MS71e 34 - - + Other than MAC
MS83 27 + + - MAV
MS92 35 + + - MAV
MS92e 35 + + + MAP
A Refers to codes blindly assigned to tissue samples
B Refers to duration of bacterial growth in days
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Furthermore, all suspect Bactec isolates were analyzed using multiplex PCR and IS900 DNA
fingerprinting by a collaborator at The Ohio State University.  Table 11 shows the IS900 copy
number detected in each sample.
Table 11: IS900 DNA Copy Number in Samples that Tested IS900 Positive after Nested PCR
Sample Code Media Type UCF IS900 Result Ohio IS900 Copy #
MS6 MGIT - 0
MS8 Bactec - 1
MS8e Bactec - 4
MS11 Bactec + 1
MS11e Bactec + 4
MS12 Bactec - 3
MS12e Bactec - 0
MS13e Bactec - 3
MS19e Bactec - 0
MS21 Bactec - 0
MS21e Bactec - 3
MS22 Bactec - 1
MS22e Bactec + 3
MS24e Bactec - 2
MS25 Bactec - 3
MS25e Bactec - 1
MS29 MGIT + 1
MS29 Bactec - nd
MS30 Bactec + 1
MS32 Bactec - 1
MS41e Bactec - 3
MS43 MGIT + nd
MS47 Bactec - 0
MS62e Bactec - 1
MS67 Bactec - 0
MS68 Bactec - nd
MS71 Bactec - nd
MS71e Bactec + nd
MS83 Bactec - 1
MS92 Bactec - 0
MS92e Bactec + 1
nd:  not determined
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 Subculture of Mycobacteria Grown in Bactec Media
All tissue samples cultured with the Bactec media system that achieved a growth index of 999
were subcultured using Mycobactosel L-J Medium slants enriched with Mycobactin J.
Approximately 6-8 weeks of incubation at room temperature was necessary in order to obseve
visible colonies on the L-J media.  Following acid-fast staining on all slant colonies, microscopic
analysis revealed that 27/28 subculture samples (96%) contained acid-fast positive bacteria.
Slant MS71e, which was confirmed as a non-MAC isolate, contains spiral-shaped, long acid-fast
bacilli, compared to normal MAC isolates where short rod-shaped bacilli arranged in clumps
were observed, as seen in Figure 12.  Genomic DNA extraction was performed on all 28
subcultured isolates, and the DNA extracts were analyzed by a panel of PCR assays as previously
described.  After PCR evaluation using 16S rRNA primers, 23/28 samples (82%) proved to
contain the 193 bp fragment of the  internal spacer region (MAC).  Twenty-four of the 28
samples (86%) gave positive results for the 427 bp IS1245 DNA array (MAV), while one sample
(4%) indicated the presence of the 298 bp IS900 DNA sequence (MAP).  Figure 13 shows the
results from all three PCR assays on a representative set of Bactec subcultures.  Table 12
summarizes all the PCR results conducted on the Bactec subcultures, and itemizeseach type of
organism detected.
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Figure 12.  Comparison of MAC Atypical versus Typical Acid-fast Bacilli Obtained from Bactec
Subcultures.
(A) illustrates sample MS71e which contains spiral-shaped, acid-fast bacilli atypical of MAC.  








Figure 13.  Complete PCR Results for a Representative Set of Bactec Subcultures.
(A) represents the 16 S rRNA Assay.  (B) represents the IS1245 Assay.  (C) represents the IS900
nested PCR Assay.  M corresponds to a 1 Kb 100 base pair DNA step ladder.  (A) Lanes 1 &
2=negative controls, Lane 3=MS5A, Lane 4=MS5B, Lane 5=MS8, Lane 6=MS8e, Lane
7=MS10, Lane 8=MS11, Lane 9=MS11e, Lane 10=MS12, Lane 11=MS47, Lane 12=MS67,
Lane 13=MS92e, Lane 14=positive control (MAV; 193 bp), Lane 15=positive control (MAP;
193 bp).  (B) Lanes 1 & 2=negative controls, Lane 3=MS5A, Lane 4=MS5B, Lane 5=MS8, Lane
6=MS8e, Lane 7=MS10, Lane 8=MS11, Lane 9=MS11e, Lane 10=MS12, Lane 11=MS47, Lane
12=MS67, Lane 13=MS92e, Lane 14=positive control (MAV; 427 bp).  (C ) Lane 1, 2,
3=negative controls (Lane 1 is empty in P90/P91 gel), Lane 4=MS5A, Lane 5=MS5B, Lane
6=MS8, Lane 7=MS8e, Lane 8=MS10, Lane 9=MS11, Lane 10=MS11e, Lane 11=MS12, Lane
12=MS47, Lane 13=MS67, Lane 14=MS92e, Lane 15 & 16=positive control {MAP; 401 bp
(P90/P91); 298 bp (Av1/Av2)}
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Table 12: Results of the 16S rRNA, IS1245, and IS900 nested PCR Assays on Positive Bactec
Subcultures





8 + + - MAV
8E + + - MAV
11 + + - MAV
11E + + - MAV
12 + + - MAV
12E + + - MAV
13E + + - MAV
19E + + - MAV
21 + + - MAV
21E + + - MAV
22 + + - MAV
22E + + - MAV
24E + + - MAV
25 + + - MAV
25E + + - MAV
32 + + - MAV
41 + + - MAV
47 + + - MAV
62E + + - MAV
67 + + - MAV
68 - + - MAV
71 - - - Other than MAC
71E - - - Other than MAC
83 + + - MAV
92 + + - MAV
92E + + + MAP
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 Mycobacterial Growth in MGIT Media
All MGIT culture tubes were evaluated for microbial activity based upon the fluorescence of the
oxygen indicator and the level of turbidity.  After six to eight weeks of incubation at 37oC with
5% CO2, specimens suspected of mycobacterial growth were prepared for genomic DNA
extraction and further PCR analysis analogous to the Bactec samples.  The averagtime span
from processing to harvesting was 8-10  weeks.  Microscopic evaluation was performed on all
MGIT samples that indicated the presence of bacterial respiration and growth which indicated the
presence acid-fast positive bacteria.  Samples that were acid-fast positive were then subjected to
PCR investigation using primers specific for the 193 bp 16S rRNA sequence indicative of MAC
and nested PCR for the 298 bp portion of the IS900 insertional element indicative of MAP.  The
results of the 16S rRNA assay showed 6/100 whereas,  MAP was detected in 20/100 following
nested PCR.  Figure 14 illustrates the 16 S rRNA PCR results, whereas Figure 15 illustrates the
nested PCR results for a representative set of positive isolates. 
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Figure 14.  16 S rRNA PCR Assay Results on a Representative Set of MGIT Cultures.
M corresponds to a 1 Kb 100 bp DNA step ladder.  Lanes 1 & 2 correspond to negative controls.
Lane 3=MS16, Lane 4=MS17, Lane 5=MS18, Lane 6=MS19, Lane 7=MS20, Lane 8=MS21,
Lane 9=MS22, Lane 10=MS23, Lane 11=MS24, Lane 12=MS25, Lane 13=MS26, Lane
14=MS27, Lane 15=MS28, Lane 16=MS29, Lane 17=MS30.  Lanes 18 & 19=positive controls




Figure 15.  IS900 Nested PCR Assay Results for a Representative Set of MGIT Cultures.
(A) corresponds to a gel containing samples after the 1st round of amplification using P90/P91
primers.  M corresponds to a 1 Kb 100 bp DNA step ladder.  Lane 1=negative control, Lane
2=MS44, Lane 3=MS45, Lane 4=MS46, Lane 5=MS47, Lane 6=MS48, Lane 7=MS49, Lane
8=MS50, Lane 9=MS51, Lane 10=MS52, Lane 11=MS53, Lane 12=positive control (MAP; 401
bp), Lane 13=negative control, Lane 14=positive control (MAP; 401 bp).  (B) corresponds to a
gel containing samples after the 2nd round of amplification using Av1/Av2 primers.  M1
corresponds to a 1 Kb 100 bp DNA step ladder.  M2 corresponds to a 1 Kb 25 bp DNA step
ladder.  Lane 1=negative control, Lane 2=positive control (MAP; 298 bp), Lane 3=negative
control, Lane 4=MS44, Lane 5=MS45, Lane 6=MS46, Lane 7=MS47, Lane 8=MS48, Lane
9=MS49, Lane 10=MS50, Lane 11=MS51, Lane 12=MS52, Lane 13=MS53, Lane 14=positive
control (MAP; 298 bp), Lane 15=negative control.
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 Sequence Analysis of  Amplified IS900 DNA Fragments  
The initial goal of DNA sequencing and analysis was to provide further support of positive PCR
results by confirming the presence of the IS900 gene specific to MAP in mycobacterial isolates.
The second objective of this exercise was to demonstrate homology to previously published
MAP nucleotide sequences while investigating any variability among specific isolate  obtained
in this study.  Seven samples that gave positive Av1/Av2 PCR results for the 298 bp IS900
fragment were selected as a representative set for DNA sequencing and subsequent analysis.
Comparative computer analysis using Blast demonstrated that the seven nucleotide sequences
obtained from CD tissues were homologs of the IS900 insertional sequence specific to MAP
found in the GenBank database (Af416985).  Figure 16 shows an alignment of the Blast results
compared to a known bovine derived IS900 gene sequence.  As shown in Table 13, 6/7 sample
DNA sequences had a G+C content of approximately 60%, analogous to that of the
mycobacterial genome (67%).  The exception was sample MS70 which contained two
mismatches where thymine was substituted for cytosine as well as an adenine and thymi e
insertion.  Consequently, the G+C content of the MS70 nucleotide sequence was calculated to be
52%, much lower than the expected 67% that is usually observed in mycobacterial sequences.
Sample sequences MS43 and MS47 were 100% homologous to the MAP IS900 gene, while
sample sequence MS46 showed 99% identity with the standard IS900 gene.  MS46 contained one
mismatch in which a guanine was substituted for an adenine at the 218 bp position.  Further
analysis revealed that the MS53 nucleotide sequence also shared 99% homology with the IS900
element.  Again, one mismatch was found in MS53 whereby the nucleotide adenine replaced an
expected guanine at the 260 bp position.  Sample MS73 was also 99% complementary to the
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standard IS900 sequence containing one thymine insertion between base pairs 202 and 203.
Sample MS92e again had 99% homology to the IS900 Map gene with an adenine insertion
between base pair 226 and 227.  Finally, sample sequence MS70 showed the most strain diversity
having 96% identity with the standard IS900 MAP gene.  MS70 contained two mismatches
where thymine was substituted for cytosine at base pair positions 198 and 201.  MS70 had an
additional two nucleotide insertions in which an adenine was added between base pairs 161 and
162 and a thymine was inserted between base pairs 202 and 203.  Further alignment and pairwise
comparison analysis revealed that strain diversity among the seven IS900 amplified sequ nces
was confined to the area between base pairs 148-260.  Homology rates among the IS900 strains
were similar to that observed when compared against bovine MAP.  Nucleotides contained
within base pairs 261-376 showed no variability compared to the IS900 gene.  
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MS43 59.72% 100.00% -- 99.54% 100.00% 99.54% 98.15% 99.54% 99.54%
MS46 60.52% 99.58% 99.58% -- 99.58% 99.15% 97.86% 99.15% 99.15%
MS47 59.21% 100.00% 100.00% 99.57% -- 99.57% 98.25% 99.57% 99.57%
MS53 59.66% 99.58% 99.58% 99.15% 99.58% -- 98.29% 99.15% 99.15%
MS70 52.83% 94.94% 96.23% 95.29% 96.23% 96.23% -- 97.17% 95.29%
MS73 60.61% 99.58% 99.57% 99.14% 99.57% 99.14% 98.71% -- 94.14%
MS92e 59.03% 99.58% 99.56% 99.12% 99.56% 99.12% 97.80% 99.12% --
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  ............A....................................T..T.T.....  MS70
  ......................................................T.....  MS73
..............................................................  MS92e





..............................................        MS70
............................................................. MS73
..................A.......................................... MS92e








GCAGCGGGTGGCCAACGACGAGGCCGCGCTGCTGGAGTTGATTGCGGCGG IS900* bp (328-376)
............................................      MS43
.................................................. MS46




............................................      MS92e
IS900* = GenBank reference number AF416985, MAP 1453 bp; bovine source.
 DISCUSSION
The specific role of mycobacteria in the pathogenesis of Inflammatory Bowel diseases, namely
CD, remains controversial despite remarkable similarities to JD, known to be caused by MAP in
ruminants.  Current research points to a multi-factorial origin for CD involving genetic mu ations
in a key inflammatory pathway that allow for mycobacterial infection.  This is followed by an
abnormal, heightened immune response which only serves to perpetuate disease progression.
The nature of MAP in its pathogenic form as a spheroplast coupled with inhibitors and
inconsistencies in laboratory techniques complicates its detection.  A clear understa ing of CD
etiology is further confounded by the co-existence of MAC subspecies, particularly MAV, in CD
tissues obtained from the same patient.  Co-infection of IBD patients may result fom the
interaction of several factors such as a compromised immune system.  Cases of UC and CD co-
infection have been recently reported in many IBD patients as well as in HIV patients.  Another
factor that might contribute to co-infection of MAC bacteria is the close evolutionary
relationships among members of the MAC and their ability to share genetic information.
Recently, the complete MAP genome sequence was published on the web site of the University
of Minnesota (www.cbc.umn.edu/ResearchProjects/AGAC/Mptb/Mptbhome.html).  The report
showed that MAC bacteria have greater than 99% genomic homology, with only 22 genes,
including the IS900 transposable element, that distinguish MAP from the remaining MAC
members.  These findings suggest that the etiological spectrum of IBD and CD is broadening
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with regard to specific pathogens.  Consequently, an effective, efficient protocol is urgently
needed for the detection and identification of closely related MAC isolates that could facilitate a
clearer picture of IBD and CD etiology, thereby enhancing diagnosis and treatment.  The
successful development and application of a molecular diagnostic typing protocol such as this is
especially significant in those cases where simultaneous infection is common in order to
differentiate between diseases present in the same patient.   Therefore, the identification of a
common PCR reaction mixture and a thermocycler protocol for the three PCR assays used in this
study has considerably enhanced the level of accuracy, sensitivity, and time needed to identify
pathogen(s) in clinical samples, most importantly, those mycobacterial agentsinvolved in the
etiology of IBD.  It is noteworthy to mention that careful optimization reduced the time needed to
run each PCR assay by half which may have great impact on future mycobacterial diagnosis.
Furthermore, such assays will resolve the accurate identification of closely related isolates that
commonly co-exist in the environment and co-infect vulnerable hosts as was observed in this
study.
Data generated from our limited sequence analysis on seven isolates investigated in this study is
significant because two of them demonstrated 100% identity to MAP from Bovine sources and
may further the understanding of CD epidemiology with regard to mode and source of MAP
transmission to humans.  Additionally, these findings support the hypothesis that CD might be a
zoonotic disease, thereby providing more credibility to those seeking better pasteuriztion
procedures for retail milk and other diary products.  As discussed earlier, MAP is known to be
the causative agent to JD which affects not only cattle, but goats, sheep and many other types of
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domestic animals.  Because MAP infiltrates the mother's milk supply, infection in young calves
is immediate.  Likewise, young children with limited immunity and genetic susceptibility who
drink insufficiently pasteurized milk are at risk for the development of IBD mainly CD.  It is not
the number of MAP isolates cultured from CD tissue that share homology to Bovine MAP that is
significant but the fact that Bovine MAP may cause CD in humans.  The other five MAP isolates
that were investigated in this study have also shown significant homology to the IS900 gene
derived from Bovine MAP.  Because IS900 genes from other animal sources have yet to be
sequenced, the specific identity and source of these isolates cannot be determined.  However, the
observed polymorphisms in these IS900 sequences may potentially match isolates from goats,
sheep, or other animals and implicate the possibility of higher transmission risks to humans.
Sequence information gathered on members of MAC, namely MAP, from IBD patients may also
have a far-reaching impact on determining the epidemiological versus geographical distribution
of CD as it relates to high-risk regions for disease transmission.  Collection of molecular
information into a national or world-wide database would provide documentation of such areas




In summary, 1)  the PCR panel developed in this study provides a specific and rapid tool for the
identification of members of the MAC in clinical samples and culture via molecular typing.  2)
Members of the MAC including MAP have been isolated from IBD patients suggesting a
mycobacterial role regarding this chronic and controversial disease.  3) The sequence analysis of
seven IS900 amplicons supports CD as an environmental health risk in regard to products
derived from domesticated animals, and 4) the genetic diversity of the isolates investigated here
emphasizes the need for a database that can document all MAC isolates from IBD patients for a
better understanding of geographical CD hot spots versus epidemiology.  The impact of these
findings is significant toward etiology, rapid diagnosis, improved treatments, and better
prevention and control of CD. 
Ultimately, this pilot study suggests that a larger scale investigation with regard to the presence
of MAP in clinical samples from IBD patients is urgently needed.  I am pleased to report that
since the conclusion of performing these experiments, an expanded study has been approved and
funded by the National Institute of Health (USA) to be carried out in Dr. Naser's laboratory at the
University of Central Florida.  This signifies the importance of the preliminary d ta reported in
this study. 
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